BrainsWay Ltd gains after FDA approves device for reducing anxiety in patients with depression

Brainsway

18/08/2021 14:11

** U.S.-listed shares  BWAY.O  of Israel-based medical
device maker up 15.2% at $8.76 premarket
    ** Company says U.S. FDA approves its Transcranial Magnetic
Stimulation (TMS) system for reduction of comorbid anxiety
symptoms in adult patients with depression  urn:newsml:reuters.com:*:nGNXP9HxY
    ** TMS is a non-invasive treatment that activates deep brain
structures by using directed electromagnetic fields, according
to the company
    ** Comorbid anxiety symptoms are common in patients with
major depressive disorder and 10 to 16 mln adults experience
moderate to severe anxiety in addition to their primary
diagnosis of depression, the company said

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325))